These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12657913)

  • 21. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
    Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
    Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Otani K; Kaneko S; Inoue Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):291-4. PubMed ID: 10096261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
    Yasui-Furukori N; Kondo T; Mihara K; Inoue Y; Kaneko S
    Psychopharmacology (Berl); 2004 Jan; 171(2):223-7. PubMed ID: 12955290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do enzyme inducers modify haloperidol decanoate rate of release?
    Pupeschi G; Agenet C; Levron JC; Barges-Bertocchio MH
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1323-32. PubMed ID: 7863019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
    Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
    Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.
    Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y; Shibata M; Ikeda K
    Ther Drug Monit; 1997 Jun; 19(3):261-4. PubMed ID: 9200764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction between carbamazepine and bromperidol.
    Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
    Nakamura A; Mihara K; Nemoto K; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):815-8. PubMed ID: 24739668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antiemetics and emetics. 26].
    Sachweh H
    Pharm Prax; 1968; 6():140-5. PubMed ID: 4387824
    [No Abstract]   [Full Text] [Related]  

  • 33. Haloperidol plasma concentrations in Taiwanese psychiatric patients.
    Lane HY; Lin HN; Hwu HG; Jann M; Hu WH; Chang WH
    J Formos Med Assoc; 1995 Nov; 94(11):671-8. PubMed ID: 8527974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes.
    He N; Zhang WQ; Shockley D; Edeki T
    Eur J Clin Pharmacol; 2002 Feb; 57(12):847-51. PubMed ID: 11936702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haloperidol plasma levels and dose optimization.
    Coryell W; Miller DD; Perry PJ
    Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enantioselective pharmacokinetics of homochlorcyclizine: disposition of (+)- and (-)-homochlorcyclizine after intravenous and oral administration of racemic homochlorcyclizine to rats.
    Nishikata M; Nakai A; Fushida H; Miyake K; Arita T; Iseki K; Miyazaki K
    J Pharm Pharmacol; 1994 Jul; 46(7):591-5. PubMed ID: 7996389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of haloperidol steady-state levels in plasma after a single test dose.
    Javaid JI; Janicak PG; Sharma RP; Leach AM; Davis JM; Wang Z
    J Clin Psychopharmacol; 1996 Feb; 16(1):45-50. PubMed ID: 8834418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.